^
Association details:
Biomarker:TNFA-L
Cancer:Cholangiocarcinoma
Drug:Clevegen (bexmarilimab) (STAB1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Low baseline serum IFNg and TNFa are predictive of response to bexmarilimab

Published date:
03/09/2022
Excerpt:
30 patients, 10 per each tumor type, were treated with bexmarilimab...At baseline, patients that saw a clinical benefit (CBR) from bexmarilimab had average serum IFNg levels of 5.11 pg/ml (SD, +/- 4.99 pg/ml) compared to 13.07 pg/ml (SD, +/- 13.26) in patients that did not respond to the treatment. Similarly serum TNFa levels 0.96 pg/ml (SD, +/- 0.74 pg/ml) in patients that benefited from bexmarilimab compared to 2.37 pg/ml (SD, +/- 1.43 pg/ml) in patients that did not respond to the treatment...Bexmarilimab works well in patients with low IFNg and TNFa levels...